Alex discusses alternative methods to randomized controlled trials for drug development, highlighting the use of digital twins and natural history cohorts for rare diseases. He delves into the significance of blockbuster drugs in the pharmaceutical industry, emphasizing their role in driving revenue and the potential for massive profits.
